
Ondansetron 8mg
Placebo
Risk Ratio
Risk Ratio
Study or Subgroup
Events
Total
Events
Total
Weight
M-H, Random, 95% CI
M-H, Random, 95% CI
2.1.1 Overall Analysis
Gurkan 2002 [25] 3 75 7 75 12.7% 0.43 [0.12, 1.59]
Kolm 2006 [29] 1 20 8 20 5.6% 0.13 [0.02, 0.91]
Korhonen 2003 [24] 1 27 1 30 3.0% 1.11 [0.07, 16.91]
Waxler 2004 [23] 7 21 8 13 39.9% 0.54 [0.26, 1.14]
Wells 2003 [22] 7 20 10 22 38.8% 0.77 [0.36, 1.63]
Subtotal (95% CI) 163 160 100.0% 0.57 [0.35, 0.91]
Total events 19 34
Heterogeneity: Tau² = 0.00; Chi² = 3.55, df = 4 (P = 0.47); I² = 0%
Test for overall effect: Z = 2.37 (P = 0.02)
2.1.2 Obstetric Patients
Wells 2003 [22] 7 20 10 22 100.0% 0.77 [0.36, 1.63]
Subtotal (95% CI) 20 22 100.0% 0.77 [0.36, 1.63]
Total events 7 10
Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2.1.3 Non-Obstetric Patients
Gurkan 2002 [25] 3 75 7 75 20.8% 0.43 [0.12, 1.59]
Kolm 2006 [29] 1 20 8 20 9.1% 0.13 [0.02, 0.91]
Korhonen 2003 [24] 1 27 1 30 4.8% 1.11 [0.07, 16.91]
Waxler 2004 [23] 7 21 8 13 65.2% 0.54 [0.26, 1.14]
Subtotal (95% CI) 143 138 100.0% 0.47 [0.26, 0.85]
Total events 12 24
Heterogeneity: Tau² = 0.00; Chi² = 2.49, df = 3 (P = 0.48); I² = 0%
Test for overall effect: Z = 2.49 (P = 0.01)
2.1.4 Ondansetron Before Spinal Opioid
Gurkan 2002 [25] 3 75 7 75 13.5% 0.43 [0.12, 1.59]
Korhonen 2003 [24] 1 27 1 30 3.1% 1.11 [0.07, 16.91]
Waxler 2004 [23] 7 21 8 13 42.3% 0.54 [0.26, 1.14]
Wells 2003 [22] 7 20 10 22 41.1% 0.77 [0.36, 1.63]
Subtotal (95% CI) 143 140 100.0% 0.62 [0.38, 1.00]
Total events 18 26
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.94 (P = 0.05)
2.1.5 Ondansetron After Spinal Opioid
Kolm 2006 [29] 1 20 8 20 100.0% 0.13 [0.02, 0.91]
Subtotal (95% CI) 20 20 100.0% 0.13 [0.02, 0.91]
Total events 1 8
Heterogeneity: Not applicable
Test for overall effect: Z = 2.05 (P = 0.04)
0.01
0.1
1
10
100
Favours Ondansetron
Favours Control